New drug hopes to keep stage III lung cancer at bay after Chemo-Radiation

NCT ID NCT07204548

Not yet recruiting Disease control Sponsor: Sun Yat-sen University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a drug called ivonescimab can help prevent lung cancer from growing back after standard chemoradiation. It involves 63 adults with stage III non-small cell lung cancer that cannot be removed by surgery. Participants will receive ivonescimab infusions for one year, and researchers will track how long the cancer stays under control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ivonescimab (also called AK112), a drug given by IV after chemoradiation
What this could lead to: If it works, this could offer a new option to delay cancer progression in patients with stage III lung cancer who cannot have surgery.
What could go wrong: This is a small, early-phase trial with only 63 participants and no comparison group. The drug may not improve outcomes and could cause side effects like immune-related inflammation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER STAGE III are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER STAGE III

Contacts and locations

Locations

Li-Kun Chen

Guangzhou, Guangzhou, 510006, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.